Cargando…

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis

INTRODUCTION: Crisaborole topical ointment, 2%, is a nonsteroidal, topical anti-inflammatory phosphodiesterase-4 (PDE4) inhibitor that is approved for the treatment of mild-to-moderate atopic dermatitis (AD). The objective of the current analysis was to compare the efficacy of crisaborole 2% relativ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thom, Howard, Cheng, Vincent, Keeney, Edna, Neary, Maureen P., Eccleston, Anthony, Zang, Chuanbo, Cappelleri, Joseph C., Cha, Amy, Thyssen, Jacob P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776944/ https://www.ncbi.nlm.nih.gov/pubmed/34877623 http://dx.doi.org/10.1007/s13555-021-00646-1

Ejemplares similares

Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
por: Thyssen, Jacob P., et al.
Publicado: (2021)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Response to the Letter to the Editor Regarding “Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systemic Literature Review and Network Meta-Analysis”
por: Fahrbach, Kyle, et al.
Publicado: (2021)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Crisaborole for atopic dermatitis
Publicado: (2019)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study
por: Eichenfield, Lawrence F., et al.
Publicado: (2023)

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Repigmentation in a patient with vitiligo on crisaborole 2% ointment
por: Tam, Idy, et al.
Publicado: (2021)

Letter to the Editor Regarding ‘Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis’
por: Luger, Thomas, et al.
Publicado: (2021)

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia
por: Li, Lijun
Publicado: (2023)

Tacrolimus ointment in the management of atopic dermatitis
por: Baldo, Antonello, et al.
Publicado: (2009)

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)
por: Schlessinger, Joel, et al.
Publicado: (2020)

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study
por: Zane, Lee T., et al.
Publicado: (2016)

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis
por: PAVLENKO, Darya, et al.
Publicado: (2023)

Validation of Patient Identification Algorithms for Atopic Dermatitis Using Healthcare Databases
por: Ortsäter, Gustaf, et al.
Publicado: (2022)

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
por: SILVERBERG, Jonathan I., et al.
Publicado: (2020)

Characteristics of Atopic Dermatitis Patients Treated with Crisaborole: Real-World Data from a Large Healthcare Provider Database in Israel
por: Weil, Clara, et al.
Publicado: (2022)

Care pathways in atopic dermatitis: a retrospective population‐based cohort study
por: von Kobyletzki, L., et al.
Publicado: (2022)

Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations
por: Carr, Warner W.
Publicado: (2013)

Clinical and Economic Burden of Pediatric Mild-to-Moderate Atopic Dermatitis: A Population-Based Nested Case–Control Study in Sweden
por: Ortsäter, Gustaf, et al.
Publicado: (2020)

Knuckle Pads Successfully Treated with 2% Crisaborole Ointment Combined with Triamcinolone Acetonide and Neomycin Plaster: A Case Report
por: Liang, Yimin, et al.
Publicado: (2023)

Anti-Inflammatory Effect of Qingpeng Ointment in Atopic Dermatitis-Like Murine Model
por: Li, Yun-Zhu, et al.
Publicado: (2013)

Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers
por: Zane, Lee T., et al.
Publicado: (2016)

The direct and indirect costs of adult atopic dermatitis
por: Manjelievskaia, Janna, et al.
Publicado: (2021)

Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey
por: Luger, Thomas, et al.
Publicado: (2022)

Reflectance Confocal Microscopy in Monitoring Atopic Dermatitis Treated with Topical Calcineurin Inhibitors
por: Bratu, Dalia, et al.
Publicado: (2023)

Compound traditional Chinese medicine dermatitis ointment ameliorates inflammatory responses and dysregulation of itch-related molecules in atopic dermatitis
por: Zhang, Rongrong, et al.
Publicado: (2022)

CSACI position statement: safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults
por: Segal, Audrey O, et al.
Publicado: (2013)

Efficacy and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis: meta-analysis of randomized clinical trials
por: £abędź, Natalia, et al.
Publicado: (2019)

Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
por: Purohit, Vivek S., et al.
Publicado: (2018)

Long‐term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
por: Nakagawa, Hidemi, et al.
Publicado: (2019)

Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case–Control Study
por: Toron, Farah, et al.
Publicado: (2021)

Potential application of PS-OCT in the safety assessment of non-steroidal topical creams for atopic dermatitis treatment
por: Duan, M. Q., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bqgdhiksrnio3ljet7o5g9drbs